ISC 2018: COMPASS Supports First-Line Aspiration With Penumbra's System
Results of the COMPASS trial showed that Penumbra's aspiration system is non-inferior to stent-retrievers as a first-line therapy to treat acute ischemic stroke. COMPASS was one of several important device trials featured at the presented at the International Stroke Conference held in Los Angeles.
You may also be interested in...
Riptide complements Medtronic's Solitaire stent retriever revascularization device for the treatment of acute ischemic stroke. The company began rolling out Riptide at this year's International Stroke Conference, which also featured the presentation of important clinical data supporting aspiration as a first-line therapy for stroke.
The company is running a pilot program to allow glioblastoma patients who use Novocure’s Optune Tumor Treating Fields device to download data from the device at home.
The company is sponsoring research on how the blood oxygen sensor feature on its Apple Watch 6 could be applied to specific health problems.